Get calcitonin gene-related peptide migraine explained clearly: what CGRP does during attacks, how it is targeted by modern treatments, and what to track.
Getting calcitonin gene-related peptide migraine explained in plain terms is genuinely useful for anyone dealing with frequent attacks, because CGRP is the molecule that modern preventive therapies are specifically designed to target. Understanding what it does in the body, why it matters during a migraine, and how treatments interact with it gives you a much stronger foundation for conversations with your neurologist. For a broader introduction to this molecule, see What Is CGRP.
CGRP is a neuropeptide: a small signaling protein made and used by nerve cells. It is produced throughout the body and plays several normal, useful roles. It helps regulate how blood vessels contract and relax, contributes to sensory transmission, and is involved in wound healing. The trigeminal nerve, the large cranial nerve responsible for sensation across the face, scalp, and structures inside the skull, contains particularly high concentrations of CGRP.
Under typical conditions, CGRP is released in modest amounts as part of normal physiology. During a migraine attack, the trigeminal system activates and floods the meningeal blood vessels (the vessels supplying the protective membranes around the brain) with CGRP. That flood is what sets off several of the most disabling features of a migraine:
The chain of events that triggers CGRP release is not fully mapped, but researchers have identified several contributing factors. Cortical spreading depression, a slow wave of electrical disruption that moves across the brain's cortex and is thought to underlie migraine aura, appears to activate the trigeminal system. Certain triggers, including hormonal fluctuations, sleep disruption, and strong sensory input, also seem to lower the threshold at which the trigeminal nerve fires.
Once the trigeminal nerve is activated, its terminals release CGRP into the spaces around the meningeal vessels. The CGRP binds to receptors on vessel walls and on nearby mast cells, triggering vasodilation and inflammation simultaneously. The pain signals that result travel back up the trigeminal nerve to the brain stem, where they are processed and amplified.
In people with very frequent or chronic migraine (15 or more headache days per month for more than three months), some researchers believe the trigeminal system stays in a partially activated state between attacks. Baseline CGRP levels in chronic migraine patients may be elevated even outside of attacks, which helps explain why prevention is more effective than acute treatment alone for high-frequency migraine.
Two broad classes of therapies now target the CGRP pathway. Your clinician is the right person to assess which, if any, is appropriate for your situation.
| Therapy Class | Mechanism | Route |
|---|---|---|
| Anti-CGRP monoclonal antibodies | Block the CGRP molecule itself, or block its receptor | Injection or IV infusion |
| Gepants | Small molecules that block the CGRP receptor | Oral tablet |
Monoclonal antibodies are large engineered proteins. Some bind directly to CGRP, neutralizing it before it can attach to a receptor. Others bind to the CGRP receptor itself, preventing the molecule from landing even if it is released. Both strategies reduce the downstream cascade of vasodilation and inflammation. Because they are large molecules, they do not cross the blood-brain barrier, so they act mainly on the peripheral trigeminal terminals and the meningeal vessels.
Gepants are small-molecule receptor blockers that can cross into the central nervous system. Some gepants are approved for acute treatment of attacks, some for daily prevention, and at least one has evidence supporting both uses. Their cardiovascular profile differs from triptans in a meaningful way: because they block CGRP's vasodilating effect rather than causing vasoconstriction, they are being studied in populations where triptans have historically been used with caution.
Only your clinician can start, stop, or change any migraine treatment, and that includes any medication in the CGRP class.
A 50 percent or greater reduction in monthly migraine days from a documented baseline is the standard benchmark headache specialists use to define a meaningful preventive response.
That benchmark sounds simple, but reaching it requires data. If you were averaging 14 migraine days per month before starting a preventive and you drop to 7, that is a textbook response. If you were averaging 14 and you drop to 13, the treatment probably is not working and your neurologist needs to know.
The challenge is that most people do not have an accurate baseline. Memory compresses and flattens pain history, especially over months. A prospective migraine diary, started before or at the same time as a new treatment, gives you and your neurologist something concrete to evaluate. See how to track migraines accurately for what to record and what to log in a migraine diary for a practical breakdown.
Whether you are on a CGRP-targeted therapy or considering one, the data points that matter most to a clinician are:
The migraine symptom checker can help you categorize your attacks consistently across time. For a structured view of whether your pattern falls into episodic or chronic territory, the chronic or episodic migraine tool walks through the key criteria. For deeper guidance on interpreting your tracked data with your doctor, see how to measure CGRP progress.
CGRP does not explain everything about migraine, and not every person with migraine responds to CGRP-targeted therapies. The biology of migraine is complex, involving multiple neurotransmitters, ion channels, and brain regions. But CGRP sits close enough to the core of the attack mechanism that targeting it has produced some of the most consistent preventive results the headache field has seen.
Understanding this molecule shifts migraine from something that "just happens" into a process with identifiable steps. Each of those steps is, in principle, something that can be measured, documented, and managed over time.
Logging your migraine days, severity, and triggers in the app builds exactly the kind of structured record that your clinician and insurer need at renewal time, whether you are starting a CGRP-targeted therapy, evaluating its effect after three months, or making a case for continued coverage. As always, talk with your doctor before making any changes to your treatment plan.
Educational, not medical advice. Migraine Tracker: CGRP Log is a personal tracking tool, not a medical device. It does not diagnose, treat, or provide medical advice. Always talk to your clinician.
Calcitonin gene-related peptide (CGRP) is a neuropeptide released in large amounts by the trigeminal nerve during a migraine attack. It dilates blood vessels around the brain, amplifies pain signals, and sustains the inflammatory cascade that drives migraine symptoms.
Gepants migraine explained: how oral CGRP receptor blockers work, who they are for, and what questions to bring to your next neurology appointment.
Learn how do CGRP antibodies work migraine prevention by blocking a key pain molecule, and what that means for tracking your response and supporting renewal.
Comparing CGRP monoclonal antibodies vs gepants? Learn how each class works, how they differ in use and timing, and what questions to bring to your clinician.
